ライフサイエンスコーパス: trimethoprim-sulfamethoxazole

1 tracycline, ormetoprim-sulfadimethoxine, and trimethoprim-sulfamethoxazole).

2 have suggested benefit with co-trimoxazole (trimethoprim-sulfamethoxazole).

3 ciprofloxacin, clindamycin, gentamicin, and trimethoprim-sulfamethoxazole.

4 oxacin, clindamycin, gentamicin sulfate, and trimethoprim-sulfamethoxazole.

5 at Y. pestis, except for chloramphenicol and trimethoprim-sulfamethoxazole.

6 ompared by testing 567 staphylococci against trimethoprim-sulfamethoxazole.

7 e mice also received antibiotic therapy with trimethoprim-sulfamethoxazole.

8 0-day outpatient course of ciprofloxacin and trimethoprim-sulfamethoxazole.

9 lls/microL, despite anti-Pc prophylaxis with trimethoprim-sulfamethoxazole.

10 penicillin, erythromycin, tetracycline, and trimethoprim-sulfamethoxazole.

11 All infants also received high-dose trimethoprim-sulfamethoxazole.

12 osporins, fluoroquinolones, penicillins, and trimethoprim-sulfamethoxazole.

13 acin, gentamicin, rifampin, minocycline, and trimethoprim-sulfamethoxazole.

14 ftriaxone, ciprofloxacin, gentamicin, and/or trimethoprim-sulfamethoxazole.

15 penicillin, and 57 (82.6%) were resistant to trimethoprim-sulfamethoxazole.

16 a penicillin or macrolide antibiotic, or for trimethoprim-sulfamethoxazole.

17 or aadA and dhfr, which confer resistance to trimethoprim-sulfamethoxazole.

18 profloxacin, and only 7% were susceptible to trimethoprim-sulfamethoxazole.

19 luded serotypes 19A and 23F was resistant to trimethoprim-sulfamethoxazole.

20 mbination with ampicillin, trimethoprim, and trimethoprim-sulfamethoxazole.

21 caused by E. coli strains with resistance to trimethoprim-sulfamethoxazole.

22 rrhea ceased in all 19 patients treated with trimethoprim-sulfamethoxazole.

23 utrients, and postdischarge prophylaxis with trimethoprim-sulfamethoxazole.

24 acycline, chloramphenicol, erythromycin, and trimethoprim-sulfamethoxazole.

25 acceptable for patients who cannot tolerate trimethoprim-sulfamethoxazole.

26 utrients, and postdischarge prophylaxis with trimethoprim-sulfamethoxazole.

27 n, aztreonam, erythromycin, clindamycin, and trimethoprim-sulfamethoxazole.

28 reptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole.

29 f resistances to beta-lactam antibiotics and trimethoprim-sulfamethoxazole.

30 s, and prior receipt of ciprofloxacin and/or trimethoprim-sulfamethoxazole.

31 esistant to nalidixic acid, cephalothin, and trimethoprim-sulfamethoxazole.

32 and ganciclovir, and lack of prescription of trimethoprim-sulfamethoxazole.

33 penicillin, erythromycin, tetracycline, and trimethoprim-sulfamethoxazole.

34 mmunodeficiency virus who could not tolerate trimethoprim-sulfamethoxazole.

35 tetracycline, gentamicin, ciprofloxacin, and trimethoprim-sulfamethoxazole.

36 in, erythromycin, imipenem, minocycline, and trimethoprim-sulfamethoxazole.

37 o penicillin, 12% to ceftazidime, and 24% to trimethoprim-sulfamethoxazole.

38 y to meropenem, piperacillin-tazobactam, and trimethoprim-sulfamethoxazole.

39 or suicidality compared with azithromycin or trimethoprim-sulfamethoxazole.

40 cies are interpreted based on human data for trimethoprim-sulfamethoxazole.

41 ycycline, 29.7% to clindamycin, and 21.6% to trimethoprim-sulfamethoxazole.

42 acin, imipenem, linezolid, moxifloxacin, and trimethoprim-sulfamethoxazole.

43 olid, minocyline, tigecycline, rifampin, and trimethoprim/sulfamethoxazole.

44 lycosides, quinolones, tetracyclines, and/or trimethoprim/sulfamethoxazole.

45 usceptibility to penicillin, macrolides, and trimethoprim/sulfamethoxazole.

46 ime (1 of 209, 0.5%), and mixed species with trimethoprim-sulfamethoxazole (1 of 366, 0.3%).

47 Intermediate resistance was detected for trimethoprim-sulfamethoxazole (10 strains) and clindamyc

48 62.2%), followed by beta-lactams (28.3%) and trimethoprim-sulfamethoxazole (11.5%), were the most com

49 ients were randomly assigned to receive oral trimethoprim-sulfamethoxazole (160 mg or 800 mg) or cipr

50 irmed Stenotrophomonas maltophilia, and oral trimethoprim-sulfamethoxazole (160 mg/800 mg) 1.5 tabs t

51 Trimethoprim-sulfamethoxazole (160/800 mg twice daily fo

52 for 7 days (n = 128 included in analysis) vs trimethoprim-sulfamethoxazole, 160/800 mg twice per day

53 and, to a lesser extent, to kanamycin (19%), trimethoprim-sulfamethoxazole (17%), and gentamicin (11%

54 infections, was more frequently resistant to trimethoprim-sulfamethoxazole (18%) than to ciprofloxaci

55 Cephalexin, 500 mg 4 times daily, plus trimethoprim-sulfamethoxazole, 320 mg/1600 mg twice dail

56 y selected isolates that were susceptible to trimethoprim-sulfamethoxazole (4 percent, P<0.001).

57 esistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole; 4 were also resistant to

58 ibility (21.2%) was significantly lower than trimethoprim-sulfamethoxazole (54.2%, P < .0001), ciprof

59 ) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (5

60 ezolid (45/45; 100%), amikacin (56/57; 98%), trimethoprim-sulfamethoxazole (57/63; 90%), and imipenem

61 ), ethambutol (92%), and sulfamethoxazole or trimethoprim-sulfamethoxazole (70%).

62 acillin-tazobactam 72.5%, ceftazidime 74.1%, trimethoprim-sulfamethoxazole 74.4%, ciprofloxacin 77.1%

63 solate combinations and overall was best for trimethoprim-sulfamethoxazole (75% for one isolate and 1

64 onsusceptible to penicillin, macrolides, and trimethoprim-sulfamethoxazole, 8 had other resistance pa

65 ythromycin (73.9%), clindamycin (65.5%), and trimethoprim-sulfamethoxazole (80%); however, categorica

66 were successfully treated in all cases using trimethoprim-sulfamethoxazole (800 mg/160 mg) twice dail

67 with sufficient on-scale MICs occurred with trimethoprim-sulfamethoxazole (89.7%).

68 n, 82%; clindamycin, 73%; levofloxacin, 73%; trimethoprim-sulfamethoxazole, 9%; and daptomycin, 9%.

69 em (94.6%), piperacillin-tazobactam (92.8%), trimethoprim-sulfamethoxazole (92.1%), and meropenem (87

70 ence implementing a protocolized approach to trimethoprim-sulfamethoxazole adverse drug reaction asse

71 Forty-two patients (35%) had 48 trimethoprim-sulfamethoxazole adverse drug reactions doc

72 zole, as compared with standard prophylaxis (trimethoprim-sulfamethoxazole alone).

73 lactamase inhibitors) and resistance spread (trimethoprim-sulfamethoxazole, amikacin, and colistin).

74 s is complicated by increasing resistance to trimethoprim-sulfamethoxazole, amoxicillin/clavulanic ac

75 Isolates were resistant to trimethoprim-sulfamethoxazole, ampicillin, and ceftriaxo

76 While the prevalence of resistance to trimethoprim-sulfamethoxazole, ampicillin, and cephaloth

77 occus spp. had high MICs of >4/76 mug/ml for trimethoprim-sulfamethoxazole, an antibiotic commonly us

78 micin, and tobramycin; 96% were resistant to trimethoprim-sulfamethoxazole and 41% to ciprofloxacin h

79 Of the EAggEc strains, 51% were resistant to trimethoprim-sulfamethoxazole and 65% were resistant to

80 showed that all strains were susceptible to trimethoprim-sulfamethoxazole and ciprofloxacin.

81 cycline (100% for all isolates), followed by trimethoprim-sulfamethoxazole and ciprofloxacin.

82 ulation and is associated with resistance to trimethoprim-sulfamethoxazole and clindamycin.

83 pRErm46 to significantly increased MICs for trimethoprim-sulfamethoxazole and doxycycline, in additi

84 With trimethoprim-sulfamethoxazole and fluoroquinolones, the

85 icillin, imipenem, gentamicin, amikacin, and trimethoprim-sulfamethoxazole and had reduced susceptibi

86 lates which were resistant to penicillin and trimethoprim-sulfamethoxazole and had the molecular prop

87 Trimethoprim-sulfamethoxazole and macrolide use were not

88 up showed a trend of increased resistance to trimethoprim-sulfamethoxazole and nitrofurantoin, it was

89 was 0 of 46 (0%) and 6 of 47 (12.80%) in the trimethoprim-sulfamethoxazole and placebo groups, respec

90 ted in vivo by treatment with the antibiotic trimethoprim-sulfamethoxazole and possibly by coinfectio

91 nt E coli; prior receipt of ciprofloxacin or trimethoprim-sulfamethoxazole and presence of a gastrost

92 boratory interpretation of in vitro MICs for trimethoprim-sulfamethoxazole and sulfamethoxazole and t

93 Additional prophylaxis included trimethoprim-sulfamethoxazole and valganciclovir.

94 th resistance to ampicillin, gentamicin, and trimethoprim-sulfamethoxazole and with susceptibility to

95 solates were found to have resistant MICs of trimethoprim-sulfamethoxazole and/or sulfamethoxazole.

96 tudy support a single breakpoint for testing trimethoprim-sulfamethoxazole and/or trimethoprim-sulfad

97 and levofloxacin among S. pneumoniae and for trimethoprim/sulfamethoxazole and azithromycin among H.

98 %) were resistant to ampicillin, 35 (90%) to trimethoprim-sulfamethoxazole, and 24 (62%) to chloramph

99 luoroquinolones, 100 percent to rifampin and trimethoprim-sulfamethoxazole, and 92 percent to tetracy

100 al variation in resistance to ciprofloxacin, trimethoprim-sulfamethoxazole, and ampicillin in communi

101 Reduced susceptibility to tetracycline, trimethoprim-sulfamethoxazole, and chloramphenicol was o

102 d oral antimicrobials: namely, azithromycin, trimethoprim-sulfamethoxazole, and ciprofloxacin.

103 pregnant women who received bed nets, daily trimethoprim-sulfamethoxazole, and combination antiretro

104 ant women with HIV receiving bed nets, daily trimethoprim-sulfamethoxazole, and combination antiretro

105 e PBP genes, and resistance to tetracycline, trimethoprim-sulfamethoxazole, and erythromycin, and the

106 lity to ceftiofur, erythromycin, tilmicosin, trimethoprim-sulfamethoxazole, and florfenicol, with som

107 to carbapenems but susceptible to aztreonam, trimethoprim-sulfamethoxazole, and fluoroquinolones.

108 -MRSA is usually susceptible to clindamycin, trimethoprim-sulfamethoxazole, and rifampin, but inducib

109 es were susceptible in vitro to clindamycin, trimethoprim-sulfamethoxazole, and rifampin.

110 illin, cefotaxime/ceftriaxone, erythromycin, trimethoprim-sulfamethoxazole, and tetracycline.

111 penem, penicillin (PEN), tetracycline (TET), trimethoprim-sulfamethoxazole, and vancomycin.

112 ropenem, penicillin, rifampin, tetracycline, trimethoprim-sulfamethoxazole, and vancomycin.

113 ttransplant therapy consisted of tacrolimus, trimethoprim/sulfamethoxazole, and prednisone (the latte

114 effect of aminopenicillin, fluoroquinolone, trimethoprim/sulfamethoxazole, and tetracycline usage on

115 As adjuvant therapy, trimethoprim-sulfamethoxazole appears to be useful in pr

116 nded-spectrum penicillins, tetracycline, and trimethoprim-sulfamethoxazole are good treatment options

117 lfadiazine with S. equi This study indicates trimethoprim-sulfamethoxazole as an acceptable surrogate

118 from the California cohort were resistant to trimethoprim-sulfamethoxazole as well as other antibioti

119 ymptomatic UTI treated with ciprofloxacin or trimethoprim/sulfamethoxazole at 2 US Veterans Affairs m

120 . emergency departments to determine whether trimethoprim-sulfamethoxazole (at doses of 320 mg and 16

121 babwe, we assigned pregnant women to receive trimethoprim-sulfamethoxazole, at a dose of 960 mg daily

122 Among patients who cannot tolerate trimethoprim-sulfamethoxazole, atovaquone and dapsone ar

123 For trimethoprim-sulfamethoxazole, CA was for both tools <86

124 n, erythromycin, tetracycline, streptomycin, trimethoprim-sulfamethoxazole, chloramphenicol, and gent

125 B. pertussis for resistance to erythromycin, trimethoprim-sulfamethoxazole, chloramphenicol, and rifa

126 Trimethoprim-sulfamethoxazole, ciprofloxacin, and pipera

127 d for the following agents: chloramphenicol, trimethoprim-sulfamethoxazole, ciprofloxacin, and rifamp

128 endent risk factor for resistance emergence (trimethoprim-sulfamethoxazole, colistin, and novel beta-

129 venous vancomycin followed by 1 week of oral trimethoprim-sulfamethoxazole combination therapy.

130 cated cellulitis, the use of cephalexin plus trimethoprim-sulfamethoxazole compared to cephalexin alo

131 81.0%) to chloramphenicol, and 93 (92.1%) to trimethoprim-sulfamethoxazole compared with 22 (62.9%),

132 ne and of presumed bacterial infections with trimethoprim/sulfamethoxazole (cotrimoxazole) was assess

133 Current antiretroviral therapy or use of trimethoprim-sulfamethoxazole did not impact the risk of

134 In 36%, trimethoprim-sulfamethoxazole dosage was elevated by cur

135 al catheter plus treatment with rifampin and trimethoprim-sulfamethoxazole eradicated the infection.

136 all prevalence of isolates nonsusceptible to trimethoprim-sulfamethoxazole, fluoroquinolones, and nit

137 onsusceptibility (intermediate/resistant) to trimethoprim-sulfamethoxazole, fluoroquinolones, or nitr

138 st gram-negative bacilli-but mostly not EPE (trimethoprim-sulfamethoxazole, fluoroquinolones, oral ce

139 Prophylaxis for PCP and toxoplasmosis with trimethoprim-sulfamethoxazole for patients with CD4 cell

140 spected UTI, treatment with ciprofloxacin or trimethoprim/sulfamethoxazole for 7 days was noninferior

141 n of E. coli isolates that were resistant to trimethoprim-sulfamethoxazole from women with community-

142 romycin (from 11 percent to 16 percent), and trimethoprim-sulfamethoxazole (from 25 percent to 29 per

143 mportant difference favoring cephalexin plus trimethoprim-sulfamethoxazole, further research may be n

144 l agents, including ampicillin, ceftazidime, trimethoprim-sulfamethoxazole, gentamicin, and ciproflox

145 the ESBL TEM-10, and mediated resistance to trimethoprim-sulfamethoxazole, gentamicin, and tobramyci

146 24-month visit for 428 children (214 in the trimethoprim-sulfamethoxazole group and 214 in the place

147 (+/-SD) birth weight was 3040+/-460 g in the trimethoprim-sulfamethoxazole group and 3019+/-526 g in

148 loped in 2 of 524 participants (0.4%) in the trimethoprim-sulfamethoxazole group and in 2 of 533 part

149 Weight gain in the trimethoprim-sulfamethoxazole group and the placebo grou

150 ed in 507 of 630 participants (80.5%) in the trimethoprim-sulfamethoxazole group versus 454 of 617 pa

151 ed in 487 of 524 participants (92.9%) in the trimethoprim-sulfamethoxazole group versus 457 of 533 pa

152 ) of 218 participants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 165 (85.5%) of 19

153 ) of 248 participants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 171 (69.0%) of 24

154 had developed in 1 participant (0.2%) in the trimethoprim-sulfamethoxazole group.

155 cin, such as teicoplanin, tetracyclines, and trimethoprim/sulfamethoxazole, have demonstrated favorab

156 entioned in 38 case reports, gold in 11, and trimethoprim-sulfamethoxazole in 10.

157 to sulfisoxazole in 21.7% of strains and to trimethoprim-sulfamethoxazole in 21.0% resulted from pol

158 s of isoniazid-pyridoxine (coformulated with trimethoprim-sulfamethoxazole in a single fixed-dose com

159 , clarithromycin, doxycycline, imipenem, and trimethoprim-sulfamethoxazole in each of four laboratori

160 Resistance to trimethoprim-sulfamethoxazole in Iran is low and this dr

161 ates the utility of prolonged treatment with trimethoprim-sulfamethoxazole in Nocardia infections.

162 ere azithromycin in the pneumonia cohort and trimethoprim-sulfamethoxazole in the UTI cohort.

163 to fluoroquinolones were identified in 59%, trimethoprim/sulfamethoxazole in 45%, and aminoglycoside

164 While trimethoprim-sulfamethoxazole is considered first-line t

165 A 1-week course of trimethoprim-sulfamethoxazole is effective in HIV-infect

166 Although trimethoprim-sulfamethoxazole is the drug of choice for

167 Trimethoprim-sulfamethoxazole is the preferred drug regi

168 usceptibility to penicillin, macrolides, and trimethoprim/sulfamethoxazole is associated with more fr

169 and treatment of Pneumocystis pneumonia with trimethoprim/sulfamethoxazole is effective in reducing t

170 lumefantrine exposure, and in the absence of trimethoprim-sulfamethoxazole, lumefantrine exposure is

171 inum isolates to be as follows (rank order): trimethoprim-sulfamethoxazole (MIC at which 90% of the i

172 ry concentration, >/=1 microg/mL) and 19% to trimethoprim/sulfamethoxazole (minimal inhibitory concen

173 to at least ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug resistant [MDR]

174 esistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant [MDR]

175 esistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant S. Ty

176 , including ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant Salmo

177 d accounted for >/=40% (beta-lactams), >50% (trimethoprim-sulfamethoxazole , multidrug), or >70% (cip

178 24), abacavir (n = 11), nevirapine (n = 14), trimethoprim-sulfamethoxazole (n = 11), dapsone (n = 4),

179 Immediate antimicrobial therapy with trimethoprim-sulfamethoxazole, nitrofurantoin, or fosfom

180 ce interval (CI), 0.60-0.97; P =.03; risk of trimethoprim-sulfamethoxazole nonsusceptibility was also

181 In this study, antibiotic prophylaxis with trimethoprim-sulfamethoxazole or levofloxacin during ind

182 Trimethoprim-sulfamethoxazole or methotrexate may be val

183 Trimethoprim-sulfamethoxazole or placebo taken orally, o

184 Additionally, each was randomized to trimethoprim-sulfamethoxazole or placebo.

185 P = 0.016) and less frequently resistant to trimethoprim-sulfamethoxazole (OR = 0.38; 95% CI = 0.18

186 cases were treated with other beta-lactams, trimethoprim-sulfamethoxazole, or vancomycin.

187 ce to amoxicillin-clavulanic acid (P = .03), trimethoprim-sulfamethoxazole (P = .01), and ciprofloxac

188 .002), and to cephalothin, trimethoprim, and trimethoprim-sulfamethoxazole (P<.001).

189 ted CAS, the most common antimicrobials were trimethoprim-sulfamethoxazole, penicillin, and amoxicill

190 penicillins alone (12%), and penicillins and trimethoprim-sulfamethoxazole plus >=1 additional antibi

191 l prophylaxis, which consisted of continuous trimethoprim-sulfamethoxazole plus at least 12 weeks of

192 Trimethoprim-sulfamethoxazole promotes the excision of a

193 nomic outcomes associated with no treatment, trimethoprim-sulfamethoxazole prophylaxis alone, antiret

194 ting and clinical criteria, as compared with trimethoprim-sulfamethoxazole prophylaxis alone.

195 A strategy of trimethoprim-sulfamethoxazole prophylaxis and antiretrov

196 Women received daily trimethoprim-sulfamethoxazole prophylaxis and insecticid

197 In Zimbabwe, trimethoprim-sulfamethoxazole prophylaxis during pregnan

198 uster, which was controlled after systematic trimethoprim-sulfamethoxazole prophylaxis in exposed pat

199 ract infection, we evaluated the efficacy of trimethoprim-sulfamethoxazole prophylaxis in preventing

200 Trimethoprim-sulfamethoxazole prophylaxis resulted in sa

201 , and no further cases were identified after trimethoprim-sulfamethoxazole prophylaxis was introduced

202 lysis of data from a large clinical trial of trimethoprim-sulfamethoxazole prophylaxis, there was no

203 re as cost-effective as those that also used trimethoprim-sulfamethoxazole prophylaxis.

204 Trimethoprim/sulfamethoxazole prophylaxis was associated

205 Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis administered

206 loxacin, rifampin, parenteral gentamicin, or trimethoprim-sulfamethoxazole provide the best therapeut

207 clinical isolates, including 3 resistant to trimethoprim-sulfamethoxazole, rapidly accumulated PABA.

208 Significantly more patients underwent trimethoprim-sulfamethoxazole rechallenge after protocol

209 The introduction of a standard approach to trimethoprim-sulfamethoxazole rechallenge in the context

210 floxacin regimen and 83% (92 of 111) for the trimethoprim-sulfamethoxazole regimen (95% CI, 0.06-0.22

211 floxacin regimen and 89% (90 of 101) for the trimethoprim-sulfamethoxazole regimen (95% confidence in

212 ologic and clinical cure rates than a 14-day trimethoprim-sulfamethoxazole regimen, especially in pat

213 atients receiving secondary prophylaxis with trimethoprim-sulfamethoxazole remained disease-free, and

214 ting P carinii pneumonia; the combination of trimethoprim-sulfamethoxazole remains the first-line age

215 (clonal group A), in 28 of 55 isolates with trimethoprim-sulfamethoxazole resistance (51 percent) an

216 foreign travel significantly predicted both trimethoprim-sulfamethoxazole resistance (prevalence rat

217 emergent pulsotype 2123 was associated with trimethoprim-sulfamethoxazole resistance and K1 (versus

218 cently recognized significant contributor to trimethoprim-sulfamethoxazole resistance in the United S

219 esistant isolate (8%) was more common than a trimethoprim-sulfamethoxazole-resistant isolate (2%).

220 cible clindamycin resistance (ICR) (n = 30), trimethoprim-sulfamethoxazole-resistant MRSA (n = 10), v

221 egimen, especially in patients infected with trimethoprim-sulfamethoxazole-resistant strains.

222 or fluoroquinolones, and 0.576 and 0.624 for trimethoprim-sulfamethoxazole, respectively.

223 f isolates were resistant to clindamycin and trimethoprim/sulfamethoxazole, respectively.

224 Cefprozil, cefaclor, and trimethoprim-sulfamethoxazole results differed the most,

225 of the four antimicrobial agents tested; the trimethoprim-sulfamethoxazole results were lower with Et

226 Trimethoprim-sulfamethoxazole retains clinical efficacy,

227 prevalence of resistance to trimethoprim and trimethoprim-sulfamethoxazole rose from more than 9% in

228 Patients treated with standard-dose trimethoprim-sulfamethoxazole should be monitored closel

229 of travel-associated infections resistant to trimethoprim-sulfamethoxazole, sulfisoxazole, streptomyc

230 enes, as well as reductions in oxacillin and trimethoprim-sulfamethoxazole susceptibility.

231 isolates (112 of 120) were also resistant to trimethoprim-sulfamethoxazole (SXT) (97 of 120 isolates,

232 Azithromycin and trimethoprim-sulfamethoxazole (SXT) are widely used to t

233 Ten days of trimethoprim-sulfamethoxazole (SXT) therapy reduces urin

234 Overall ciprofloxacin (CIP), trimethoprim-sulfamethoxazole (SXT), and cefazolin (CFZ)

235 us urinae has been described as resistant to trimethoprim-sulfamethoxazole (SXT), but the test medium

236 maining patients were randomized to Group 1 (trimethoprim/sulfamethoxazole tablet every 2 days) or Gr

237 e acceptable for all drugs tested except for trimethoprim-sulfamethoxazole testing by the Etest.

238 and cyclosporiasis ceased more rapidly with trimethoprim-sulfamethoxazole than with ciprofloxacin.

239 For aztreonam and trimethoprim-sulfamethoxazole, the modal MICs were eleva

240 However, for children receiving trimethoprim-sulfamethoxazole, the risk of recurrent par

241 Standard-dose trimethoprim-sulfamethoxazole therapy used to treat vari

242 1.09 to 1.32 mmol/L) 4.6 +/- 2.2 days after trimethoprim-sulfamethoxazole therapy was initiated.

243 Trimethoprim/sulfamethoxazole therapy resulted in a 100%

244 8; 100%), and 90% of isolates tested against trimethoprim-sulfamethoxazole (TMP-SMX) (117/130) were s

245 drug (27%), followed by phosphomycin (23%), trimethoprim-sulfamethoxazole (TMP-SMX) (9%), and cefuro

246 Trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinol

247 Daily trimethoprim-sulfamethoxazole (TMP-SMX) and insecticide-

248 Long-term antibiotic therapy included oral trimethoprim-sulfamethoxazole (TMP-SMX) and rifampin, TM

249 Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly pre

250 a 1:1 ratio to receive either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) for 10 days.

251 drugs for at least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 wee

252 drugs like HIV protease inhibitors (PIs) and trimethoprim-sulfamethoxazole (TMP-SMX) have known activ

253 rophylaxis (SBPPr) with fluoroquinolones and trimethoprim-sulfamethoxazole (TMP-SMX) is often used, r

254 Trimethoprim-sulfamethoxazole (TMP-SMX) is widely used f

255 Trimethoprim-sulfamethoxazole (TMP-SMX) is widely used i

256 up to 42 days, primarily in those receiving trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

257 44) or HIV exposed (n = 175) and prescribed trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

258 Late in the course of this trial, trimethoprim-sulfamethoxazole (TMP-SMX) was incorporated

259 lin, 649 (58%) to streptomycin, 402 (36%) to trimethoprim-sulfamethoxazole (TMP-SMX), 355 (32%) to su

260 sequently, some centers have transitioned to trimethoprim-sulfamethoxazole (TMP-SMX), an inexpensive

261 in, 19 isolates (43%) were nonsusceptible to trimethoprim-sulfamethoxazole (TMP-SMX), and all isolate

262 amikacin, ciprofloxacin, imipenem, rifampin, trimethoprim-sulfamethoxazole (TMP-SMX), and vancomycin.

263 ibiotic prescription fill of nitrofurantoin, trimethoprim-sulfamethoxazole (TMP-SMX), fluoroquinolone

264 re randomly assigned to receive clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), or placebo for

265 ortant has been the increasing resistance to trimethoprim-sulfamethoxazole (TMP-SMX), the current dru

266 Additionally, trimethoprim-sulfamethoxazole (TMP-SMX), used for opport

267 of urinary tract infections (UTI) caused by trimethoprim-sulfamethoxazole (TMP-SMX)-resistant Escher

268 Trimethoprim-sulfamethoxazole (TMP-SMZ) and the fluoroqu

269 Trimethoprim-sulfamethoxazole (TMP-SMZ) is an alternativ

270 Trimethoprim-sulfamethoxazole (TMP-SMZ) is the most effe

271 han other adults, and many receive long-term trimethoprim-sulfamethoxazole (TMP-SMZ) prophylactic the

272 were less likely than controls to have used trimethoprim-sulfamethoxazole (TMP-SMZ) prophylaxis (odd

273 these organisms is typically susceptible to trimethoprim-sulfamethoxazole (TMP-SMZ), and this theref

274 The efficacy of trimethoprim-sulfamethoxazole (TMP/SMX) in the preventio

275 iving antiretroviral therapy (ART) and daily trimethoprim-sulfamethoxazole (TMP/SXT).

276 oramphenicol, doxycycline, sulfadiazine, and trimethoprim-sulfamethoxazole [TMP-SMX]) and abstracted

277 While antifolates such as Bactrim (trimethoprim-sulfamethoxazole; TMP-SMX) continue to play

278 is, controlled either with no prophylaxis or trimethoprim/sulfamethoxazole (TMS) prophylaxis.

279 cellulitis without abscess, the addition of trimethoprim-sulfamethoxazole to cephalexin did not impr

280 Among trimethoprim-sulfamethoxazole-treated patients, drug res

281 ofloxacin-treated patients and in 33% of 187 trimethoprim-sulfamethoxazole-treated patients, respecti

282 In settings in which MRSA was prevalent, trimethoprim-sulfamethoxazole treatment resulted in a hi

283 Eighty patients treated with standard-dose trimethoprim-sulfamethoxazole (trimethoprim, < or = 320

284 onthly sulfadoxine-pyrimethamine (SP), daily trimethoprim-sulfamethoxazole (TS), or monthly dihydroar

285 0.002) for M. avium complex bacteremia, and trimethoprim-sulfamethoxazole use was associated with de

286 were sensitive to minocycline, doxycycline, trimethoprim-sulfamethoxazole, vancomycin, teicoplanin,

287 roportion of isolates that were resistant to trimethoprim-sulfamethoxazole was 63% in the prophylaxis

288 Trimethoprim-sulfamethoxazole was associated with slight

289 ntly prescribed antibiotic at the beginning, trimethoprim-sulfamethoxazole was most frequently prescr

290 Resistance to trimethoprim-sulfamethoxazole was significantly higher a

291 Trimethoprim-sulfamethoxazole was superior to placebo wi

292 ntly prescribed antibiotic at the beginning, trimethoprim-sulfamethoxazole was the most frequently pr

293 oxycycline (20 mg or 100 mg), cephalexin, or trimethoprim/sulfamethoxazole], we investigated microbia

294 em, levofloxacin, meropenem, tobramycin, and trimethoprim-sulfamethoxazole were comparable for the tw

295 n, penicillin, tetracycline, tilmicosin, and trimethoprim-sulfamethoxazole were determined for each i

296 and N. otitidiscaviarum were susceptible to trimethoprim-sulfamethoxazole, while 8% of N. farcinica

297 Children not receiving trimethoprim-sulfamethoxazole with capillary whole blood

298 Prophylaxis most frequently involves trimethoprim-sulfamethoxazole, with second-line therapie

299 signed to receive placebo and 495 to receive trimethoprim-sulfamethoxazole, with the first dose recei

300 To determine whether cephalexin plus trimethoprim-sulfamethoxazole yields a higher clinical c